Posted on April 20, 2016 · Posted in cardiology, familial hypercholesterolemia, FH, health, lipids, medication, medicine, News, statins

Important research recently published in the American Heart Association’s journals illustrates that the cardiovascular disease burden and treatment patterns among patients with familial hypercholesterolemia (FH) in the US remain poorly described. The study consisted of a cross-sectional analysis of 1295 adults with heterozygous FH enrolled in the FH Foundation’s CASCADE-FH Registry from 11 US lipid clinics.

You can read the abstract here:

Treatment Gaps in Adults with Heterozygous Familial Hypercholesterolemia in the United States: Data from the CASCADE-FH Registry